ILIAS Biologics is at the forefront of exosome therapeutics, focusing on innovative technologies that enhance drug delivery and target specific diseases. Their EXPLOR® platform allows for the free-form loading of large protein therapeutics, such as antibodies, into exosomes using optically reversible protein-protein interactions. This method enables the effective intracellular delivery of various therapeutic agents, including intracellular antibodies and gene-editing proteins, by allowing the cargo to remain functionally active. This contrasts with traditional methods that require irreversible anchoring of the cargo to the exosome membrane, thus expanding the potential applications of exosome-based therapies.

In addition to EXPLOR®, ILIAS employs the Exo-Target® platform, which enhances the targeting capabilities of exosomes. This technology leverages the natural tropism of exosomes and surface engineering to improve the delivery of therapeutics across biological barriers, such as the blood-brain barrier (BBB). By modifying the surface of exosomes, ILIAS can facilitate targeted drug delivery to specific organs and cells, addressing significant challenges in treating conditions with limited therapeutic access. Together, these platforms position ILIAS Biologics as a leader in developing next-generation therapies for various diseases, including inflammatory conditions and cancer.

South Korea

At ILIAS Biologics, we dedicate ourselves to the paradigm-shifting advances in human medicine.
We are specialized in developing engineered exosomes by loading large therapeutic payloads inside exosomes via our proprietary platform technology, EXPLOR®. By harnessing the power of our engineered exosomes, we can deliver therapeutic proteins to the undruggable intracellular pathways to treat life-threatening and hard-to-treat rare diseases.
With a strong belief and the power of open innovation, we are expanding our global network of research and business alliances to maximize our potential in the development of the novel exosome platform technology.

ILIAS Biologics

Company Details